723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study

The post hoc analysis of the ALLEGRO-LT study evaluated the efficacy of ritlecitinib in 447 de novo patients with alopecia areata (AA) and ≥25% hair loss. After 15 months of treatment, patients with less than 95% hair loss at baseline achieved median SALT scores of <2.4, indicating almost complete scalp hair regrowth. In contrast, patients with ≥95% hair loss at baseline showed more refractory disease, but over one-third achieved a clinically meaningful SALT response (SALT ≤20 and SALT ≤10) by Month 15. Overall, ritlecitinib demonstrated efficacy in patients with varying extents of hair loss, including those with extensive hair loss at baseline.